Background {#s1}
==========

Tyrosine kinase 2 (*TYK2*), a member of the Janus kinase (JAK) family, is associated with the receptors of type I interferon (IFN), interleukin (IL)-6, IL-10, IL-12, and IL-23, has a key role in the signal transduction of these cytokines, most prominently IFNα/β ([@B1], [@B2]). IFN and some other cytokines, which are the critical roles in multiple adaptive and innate immune responses, transduce signals through the JAK-STAT path. Type I interferons signal through IFNAR1 and IFNAR2, which, respectively, associate with *TYK2* and *JAK1*.When the cytokines bind and induce the dimerization of their receptors, receptor-associated JAKs become phosphorylated and activated. Subsequently, the activated JAKs can phosphorylate the downstream substrates, the signal transducers and activators of transcription (STAT) molecules, then dimerizing and translocating to the nucleus for activating the particular genes transcription ([@B3], [@B4]). Minegishi et al. reported the first *TYK2*-deficient patient (P1) in 2006. The patient was Japanese with the triad of HIES signs ([@B5]). Interestingly, unlike P1, the HIES features were not displayed by the other 7 *TYK2*-deficient patients (P2-P8) recently recognized by Kreins et al. ([@B1]). No high serum IgE concentration, atopy, nor staphylococcal disease observed in them. They exhibited intracellular bacteria and/or viral infections, and the most typical feature is BCG disease. Therefore, it was proposed that human *TYK2* deficiency is a distinctive PID entity clinically and different from the formerly identified patients with AR-HIES ([@B6]). According to the categorization reported by the IUIS, International Union of Immunological Societies, *TYK2* deficiency was classified into Mendelian Susceptibility to Mycobacterial Disease (MSMD) ([@B7], [@B8]).

In this study, we report a novel *TYK2* gene mutation c.2395G\>A in a Chinese patient with BCG disease using whole-exome sequencing analysis. We further summarized the clinical manifestations, gene mutations, and related cytokine responses of all reported patients with *TYK2* deficiency to review the knowledge about *TYK2* deficiency. This study was performed according to the Declaration of Helsinki (1975) with approval from the local ethics committee (ID: MRCTA, ECFAH of FMU \[2019\]218) of the first affiliated hospital of Fujian medical university.

Case Presentation {#s2}
=================

History
-------

The patient was a boy at the age of 1 year and 11 months, the second child in the family (parents are young and nonconsanguineous), who was born in 2016 and vaccinated with BCG vaccine on the third day after birth. He was hospitalized in our hospital for bacterial pneumonia. After intradermal injection of BCG, repeated abscess and ulceration occurred at the injection site and gradually healed at 10 months. At the age of 14 months, he was hospitalized with enlarged left axillary lymph nodes. The diagnosis of BCG associated lymph node tuberculosis was made with positive staining for acid-fast bacilli and isolated Mycobacterium Bovis BCG from the discharging axillary sinuses. Chest X-ray showed no lung involvement. After the drainage of lymph node and external application of Chinese herbal medicine, the regional lymphadenopathy regressed to normal. He also suffered from recurrent respiratory tract infections (had pneumonia or upper respiratory tract infection every 1--2 months) and diarrhea since the age of 6 months (sensitive to the food firstly contacted). Pathogens found during multiple hospitalizations included Salmonella, Mycoplasma pneumonia, and Mycobacterium Bovis BCG. No considerable viral or fungal infections have happened so far. No high serum IgE concentration, atopy, staphylococcal illness, or lymphopenia was found for him. He started to say some simple words at the age of 3 years and 4 months with normal motor development. Physical examination revealed a small head circumference. His mother\'s brother and sister coughed and repeatedly wheezed in childhood.

Immunologic Assessments
-----------------------

These data were collected when the patient was 1 year and 11 months old. The absolute eosinophil count and lymphocyte count were normal. Immunoglobin: serum IgG, IgA, IgE, and IgM levels were normal. Lymphocyte classification: the percentage of CD3^+^T cells, CD3^+^CD4^+^CD8^−^T cells, CD3^+^CD8^+^CD4^−^T cells were within the range of normal, whereas the percentage of CD45^−^CD19 ^+^ cells were higher than the normal range, and CD3^−^CD16 /CD56^+^ cells were lower ([Table 1](#T1){ref-type="table"}).

###### 

Immunologic parameters of our patient.

  **Immunologic parameters**                     **Patient**   **Normal value**
  ---------------------------------------------- ------------- ------------------
  Absolute lymphocyte count,/mm^3^               5,550         800--4,000
  Absolute eosinophil count, /mm^3^              270           20--500
  IgG, g/L                                       3.43          3--10
  IgM, g/L                                       1.94          0.45--2.39
  IgA, g/L                                       0.23          0.14--1.08
  IgE, IU/ml                                     27.4          ≤ 49
  T cells, CD3^+^, %                             63.2          53.88--72.87
  B cells, CD19^+^, %                            26.6          7.21--20.90
  CD4^+^ cells, %                                35.9          24.08--42.52
  CD8^+^ cells, %                                19.3          19.00--32.51
  Natural Killer cells, CD3^−^CD16 /CD56^+^, %   3.6           13.23--26.39

Pathogens of Respiratory Tract Infection
----------------------------------------

Data was collected after the patient was hospitalized. The results showed positive - IgM antibodies to the influenza A & B virus. which suggested the current or recent infection. IgM antibodies to m. pneumoniae and m. pneumoniae antibodies are positive (1: 160), which revealed the existence of mycoplasma pneumonia ([Table 2](#T2){ref-type="table"}).

###### 

Pathogen detection results.

  **IgM-type antibodies**              **Patient**     **Normal value**
  ------------------------------------ --------------- ------------------
  IgM to respiratory syncytial virus   negative (-)    negative (-)
  IgM to adenovirus                    negative (--)   negative (--)
  IgM to influenza A virus             positive (+)    negative (--)
  IgM to influenza B virus             positive (+)    negative (--)
  IgM to parainfluenza virus           negative (--)   negative (--)
  IgM to M. pneumoniae                 positive (+)    negative (--)
  IgM to M. tuberculosis               negative (--)   negative (--)
  IgM to legionella pneumophila        negative (--)   negative (--)
  M. pneumoniae antibody (mp ab)       1: 160          1: 40

Gene Mutation Screening
-----------------------

We investigated the *TYK2* gene of the members of this family except for the brother by WES (whole exon sequencing). Mutations were found in four genes, including *TYK2* (c.2395G\>A, p.G799R, hom), *CFH* (c.2089C\>T, p.L697F, het), *LRRC8A* (c.1250G\>A, p.R417Q, het) and *NIPBL* (c.5575-27_c.5575-26delCT, --, het). The pathogenic evidences of these mutations in *CFH, LRRC8A* and *NIPBL* are insufficiency, but the possible variations of pathogenicity could not be excluded. Sequence analysis demonstrated the homozygous missense mutation in the exon 17 of the *TYK2* gene of the patient, which was heterozygous in his parents ([Figure 1](#F1){ref-type="fig"}).

![A homozygous missense mutation in exon 17 of the *TYK2* gene in our patient.](fped-08-00253-g0001){#F1}

*TYK2* Mutation (c.2395G\>A) *in vivo* and *in vitro*
-----------------------------------------------------

qRT-PCR was carried out to detect the expression of *TYK2* in patient-derived cells with the forward primer (5′-3′ CAGATCAGACAGCACAGGGG) and the reverse primer (5′-3′ GCAGTCCTTGAAGCTGGTCT). The results showed that this mutation leads to a decrease of TYK*2* mRNA expression ([Figure 2A](#F2){ref-type="fig"}). Besides, the western blot results showed that no TYK2 protein expression found in the patient ([Figure 2B](#F2){ref-type="fig"}). To verify the effects of c.2395G\>A on TYK2 deficiency, an *in vitro* experiment was carried out. The effects of c.2395G\>A mutation on the *TYK2* gene and protein expression were revealed using two types of plasmids: p3XFLAG-CMV-7.1- TYK2 (FLAG-TYK2) and pEGFP-N1-TYK2 (TYK2-GFP). We investigated c.2395G\>A (p.G799R) mutant introduced into the HEK293T cell line ([Figure 3A](#F3){ref-type="fig"}). The qRT-PCR results showed that this c.2395G\>A mutant decreased the expression of FLAG-TYK2 and TYK2-GFP ([Figure 3B](#F3){ref-type="fig"}). To go along with this, this mutant also decreased the expressed protein of FLAG-TYK2 and TYK2-GFP in the western blot analysis ([Figure 3C](#F3){ref-type="fig"}).

![The expression of *TYK2* in these family members. **(A)** The qRT-PCR results of the patient and health control. **(B)** Western blot analysis results of Tyk2 protein in patient and health control.](fped-08-00253-g0002){#F2}

![Expression of *TYK2* in wild type and c.2395G\>A mutant HEK293T cell line. **(A)** The sanger analysis results of wild type and c.2395G\>A mutant HEK293T cell; **(B)** mRNA expression of FLAG-TYK2 and TYK2-GFP in both wild type and c.2395G\>A mutant HEK293T cell; **(C)** Western blot analysis results of FLAG-TYK2 and TYK2-GFP in both wild type and c.2395G\>A mutant HEK293T cell.](fped-08-00253-g0003){#F3}

Discussion {#s3}
==========

Clinical Manifestations
-----------------------

Including our patient, there are 12 patients reported with *TYK2* deficiency ([@B1], [@B2], [@B5], [@B9]) ([Table 3](#T3){ref-type="table"}), with the average age at diagnosis of 10.8 years old. Seven patients (58%) suffered from intracellular bacterial infections. M. tuberculosis was observed in 2 cases (17%). Seven patients had recurrent virus infections (58%). Rash or atopic dermatitis eczema was observed in 2 patients (17%). Markedly increased serum IgE occurred in 3 cases (25%), and EBV-related B lymphoma and T cells lymphopenia were reported in 2 cases (17%). Different from type I high IgE syndrome caused by STAT3 mutation, none of the 12 patients had special facial features, abnormal bone development or pathological fractures, delayed deciduous tooth loss, or aneurysms.

###### 

Information about reported TYK2-deficient patients.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
          **First author**   **Sex**     **Country**   **Age**   **Atopy/**\      **High IgE levels**   **S. aureus infection**   **Viral infection**                         **Intracellular bacterial infection**   **Fungal infection**   **BCG vaccination**   **Gene mutation**                                                  **Protein mutation**
                                                                 **dermatitis**                                                                                                                                                                                                                                                       
  ------- ------------------ ----------- ------------- --------- ---------------- --------------------- ------------------------- ------------------------------------------- --------------------------------------- ---------------------- --------------------- ------------------------------------------------------------------ ----------------------
  P1      Minegishi          M           Japan         22        yes              yes                   yes                       HSV, PI3, MC                                BCG *Salmonella*                        C. albicans            yes                   Exon 4 c.550_553delGCTT                                            C70HfsX21

  P2      Kreins             M           Turkey        17        no               no                    no                        VZV                                         BCG, *Brucella*                         no                     yes                   Exon 16 c.2303_2311del                                             L767X

  P3      Kreins             F           Morocco       14        no               no                    no                        no                                          *M. tuberculosis*                       no                     yes                   Exon23 c.3318_3319insC                                             T1106HfsX4

  P4      Kreins             M           Morocco       14        no               no                    no                        unknown                                     unknown                                 no                     yes                   Exon23 c.3318_3319insC                                             T1106HfsX4

  P5      Kreins             M           Iran          5         no               no                    no                        no                                          BCG                                     no                     yes                   Exon5 c.462G\>T                                                    E154X

  P6      Kreins             F           Iran          2         no               no                    no                        yes                                         BCG                                     no                     yes                   Exon5 c.462G\>T                                                    E154X

  P7      Kreins             F           Iran          9         no               no                    no                        no                                          *M. tuberculosis*                       no                     yes                   Exon3 c.149delC                                                    S50HfsX1

  P8      Kreins             M           Argentina     11        no               no                    no                        HSV                                         No                                      no                     yes                   Exon13 c.1912 C\>T                                                 R638X

  P9      Fuchs              M           Kurdish       5         yes              yes                   yes                       no                                          No                                      no                     no                    Exon7 c.647delC                                                    P216RfsX14

  P10     Nemoto             M           unknown       15        no               no                    no                        EBV-associated B-cell lymphoma, varicella   No                                      no                     yes                   compound heterozygous mutations c.209_212 del GCTT /c.691 C \> T   C70SfsX21/R231W

  P11     Nemoto             F           unknown       14        no               no                    no                        EBV-associated B-cell lymphoma, Varicella   Unknown                                 no                     yes                   compound heterozygous mutations c.209_212 del GCTT /c.691 C \> T   C70SfsX21/R231W

  P12     Peilin             M           China         2         no               no                    no                        Influenza virus                             MP, BCG                                 no                     yes                   Exon17 c.2395G\>A                                                  G799R

  Total                      M:F = 8:4                 10.8      2/12 (0.17)      2/12 (0.17)           2/12 (0.17)               7/12 (0.58)                                 7/12 (0.58)                             1/12 (0.08)            11/12 (0.92)                                                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*BCG, Bacillus Calmette -- Guerin; MP, mycoplasma pneumonia*.

Pathogenesis
------------

The mammalian JAK family has four members: JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2). Tyk2 as an essential element, which is activated by an array of cytokine receptors in IL-12 and type I-IFN signaling. A mutation in this gene has been associated with HIES ([@B5], [@B10]). In this case, c.2395G\>A is a missense mutation that causes the amino acid to change from G to R, which may restrict the function of TYK2 protein. Our results also support this inference, and we did observe decreases in gene expression and protein levels in patient-derived cells and HEK293T cells. Although HEK293T cells have lower background factors, they still cannot fully simulate patient-derived cells, so the results of the two cells are somewhat different, but at least the trends of both cell types are consistent. For its pathogenic mechanism, viral and/or mycobacterial infections are the main clinical phenotypes of *TYK2* deficiency, initiated by diminished reactions to IL-12 and IFN-α/β. A key cytokine in generating and regulating the cellular immune response needed for the elimination of intracellular pathogens from macrophages is IFN-γ. *TYK2* mediates signal transduction between cytokine receptors and STATs. Both IL-12 and IL-23 can promote the production of IFN-γ. *TYK2* mutation weakened the response of NK and T cells to IL-12 and IL-23, resulting in insufficient IFN-γ creation ([@B11], [@B12]). When cells cannot secrete normal levels of IFN-γ, they are vulnerable to poorly pathogenic mycobacteria, and develop into MSMD ([@B12]). In addition, the main factor of the innate antiviral defense of all cells is represented by IFN-α/β ([@B13]). The largely impaired or abolished of IFN-α/β responses probably contribute to the incremented sensitivity to viral infections. However, virus control via type-III IFN (IFN-λ) signals could be a compensatory role contributing to the mild phenotype in *TYK2* deficient patients regardless of an intense decrease in IFN-α/β mediated antiviral activity ([@B14]). Nemoto reported a recessive partial *TYK2* deficiency in two siblings who presented with T-cell lymphopenia characterized by low naïve CD4+ T-cell counts and who developed EBV-associated B-cell lymphoma ([@B2]). *TYK2*-deficient patients presented with infections associated with the herpesvirus family ([@B1]), thus, *TYK2*-deficient patients might be susceptible to EBV ([@B15]). Correspondingly, it was observed that not all *TYK2*-deficient patients had poor control of the virus. Among these informative patients, no incremented susceptibility to viral infections was found nearly in half of them. Very mild candidiasis was found in P1 (restricted to a small number of episodes of slight oral candidiasis), not in P2-P11, and P12. The normal circulating IL17 T cells probably explained their apparent lack of CMC. The response to IL-23 is weakened but not stopped in *TYK2*-deficient patients. The susceptibility of the patient to extracellular bacteria might be described at least partly by the deficiency in IL-23 signaling. The high quantity of serum IgE and the atopic dermatitis-like skin inflammation in the patient could be caused by the hastened Th2 differentiation. *TYK2* mutation probably promotes Th2 cell differentiation, leading to incremented producing of IL-4, IL-5, and IL-13, associated with atopic dermatitis and eczema. Besides, different mutation types may have different impact on the expression of *TYK2*, which lead to different patient characterization. Sequencing results implied that our patient carried novel missense homozygous mutation (c.2395G\> A, p. G799R) in the *TYK2*. As a supplement, this mutation type was is included in the genome Aggregation Database (gnomAD), suggesting that this was not a private mutation. The CADD_score, GDI and MSC-SIFT_Score were A:25.6, 1605.550 and 0.243, respectively. Patients comes from consanguineous family might have other defects in addition to the TYK2 deficiency, which might influence the clinical phenotype.

Differential Diagnosis
----------------------

All the 12 reported *TYK2*-deficient patients were infected by potential infection source (S. aureus infection/Viral infection/Intracellular bacterial infection/Fungal infection), which might be one of the important indicators for diagnosis. In addition, high serum IgE concentration is not universal in *TYK2*-deficient patients. In our *TYK2* deficiency case, he was sensitive to the food firstly contacted, which indicated the intolerance to bacteria. Also, the family history of childhood wheezing cannot be ignored. Combined with the reported *TYK2* deficiency cases, we summary the main features of *TYK2* deficiency: (a) *TYK2* gene mutation; (b) Autosomal recessive inheritance; (c) The number of lymphocytes is normal, and multiple cytokine signaling defect; (d) Susceptibility to viruses or intracellular bacteria; (e) With/without elevated IgE. Therefore, the possibility of *TYK2* deficiency should be considered when a patient has repeated intracellular bacteria (including tuberculosis bacillus infection), repeated viral infection or eczema, especially with a family history. An accurate genetic diagnosis could indicate susceptible pathogens conducive to accurate treatment.
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